The coverage of all ERBB2 exons in the tumor sample with fusion was within the 95% CI of the exon coverage in breast cancer samples, as well as above the 95th percentile exon coverage of normal breast tissue samples (data not shown). This evidence concerns the gene ERBB2 and breast cancer.